Risk factors for serious infections in ANCA-associated vasculitis
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

  • Published on:
    Correspondence on "Risk factors for serious infections in ANCA-associated vasculitis" by Odler et al

    I am writing in regards to the article, "Risk factors for serious infections in ANCA-associated vasculitis" by Odler and colleagues, which published in the Annals of Rheumatic Diseases1. While the study provides valuable information on the risk factors for severe infections in patients with ANCA-associated vasculitis (AAV), there are certain limitations that must be taken into consideration when interpreting the results. One of the significant limitations of the study is the small sample size of only 197 patients. This limited sample size raises questions about the generalizability of the results and their statistical significance. The study results may only be applicable to the population represented in the sample and may not reflect the experiences of larger patient populations. Moreover, the small sample size may increase the likelihood of type I or type II errors and make it difficult to identify significant associations2. Another important limitation is that the study only includes participants from the RAVE trial, which is a specific population of AAV patients who meet certain inclusion criteria. Therefore, the results may not be generalizable to the broader population of AAV patients, who may have different risk factors, underlying comorbidities, and other factors that may impact the risk of severe infections3. Furthermore, the lack of a control group is another limitation of the study. The study only compared patients receiving rituximab or cyclophosphami...

    Show More
    Conflict of Interest:
    None declared.